The purpose of this core facility is to provide a centralized resource to the members of the San Antonio Cancer Institute (SACI) for the design, implementation and evaluation of preclinical and clinical pharmacological studies of antitumor compounds or biologicals.
The specific aims and functions of this shared facility are the following: a. Collaborate in the design of clinical and laboratory studies. Reviews all research protocols and makes recommendations from a pharmacological point of view, taking into account limitations of sample volume, assay sensitivity, equipment, personnel, time and cost. b. Implement or develop suitable analytical methodologies under GLP guidelines for the measurement of drug concentrations in biological fluids and/or tissues. c. Perform studies in tissues, animals, or humans of the absorption, clearance, tissue distribution, metabolism and urinary/fecal excretion of compounds after parenteral, oral or regional administration. d. Provide pharmacokinetic data analyses through the use of both commercially available and customized computer programs followed by a report and interpretation of the data. e. Provide education and training to students, postdoctoral fellows, and investigators in the performance of preclinical/clinical pharmacology studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA054174-06
Application #
5209106
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
1996
Total Cost
Indirect Cost
Wei, Zhen; Panneerdoss, Subbarayalu; Timilsina, Santosh et al. (2018) Topological Characterization of Human and Mouse m5C Epitranscriptome Revealed by Bisulfite Sequencing. Int J Genomics 2018:1351964
Deng, Yilun; Qin, Yuejuan; Srikantan, Subramanya et al. (2018) The TMEM127 human tumor suppressor is a component of the mTORC1 lysosomal nutrient-sensing complex. Hum Mol Genet 27:1794-1808
Zanotto-Filho, Alfeu; Rajamanickam, Subapriya; Loranc, Eva et al. (2018) Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells. Cancer Lett 425:101-115
Chiang, Huai-Chin; Zhang, Xiaowen; Zhao, Xiayan et al. (2018) Gene-Specific Genetic Complementation between Brca1 and Cobra1 During Mouse Mammary Gland Development. Sci Rep 8:2731
Donegan, Jennifer J; Boley, Angela M; Lodge, Daniel J (2018) Embryonic stem cell transplants as a therapeutic strategy in a rodent model of autism. Neuropsychopharmacology 43:1789-1798
Segovia, Jesus A; Chang, Te-Hung; Winter, Vicki T et al. (2018) NLRP3 Is a Critical Regulator of Inflammation and Innate Immune Cell Response during Mycoplasma pneumoniae Infection. Infect Immun 86:
Cepeda, Sergio; Cantu, Carolina; Orozco, Stephanie et al. (2018) Age-Associated Decline in Thymic B Cell Expression of Aire and Aire-Dependent Self-Antigens. Cell Rep 22:1276-1287
Vaidya, Anand; Flores, Shahida K; Cheng, Zi-Ming et al. (2018) EPAS1 Mutations and Paragangliomas in Cyanotic Congenital Heart Disease. N Engl J Med 378:1259-1261
Ramasamy, Kumaraguruparan; Balasubramanian, Sowmya; Manickam, Krishnan et al. (2018) Mycoplasma pneumoniae Community-Acquired Respiratory Distress Syndrome Toxin Uses a Novel KELED Sequence for Retrograde Transport and Subsequent Cytotoxicity. MBio 9:
Snead, Wilton T; Zeno, Wade F; Kago, Grace et al. (2018) BAR scaffolds drive membrane fission by crowding disordered domains. J Cell Biol :

Showing the most recent 10 out of 989 publications